Handelsavisen
prelaunch
Companies Healthcare NYR.AX
NY
NYR.AX ASX Biotechnology & Medical Research

Nyrada Inc

A$0,44
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Nyrada Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing diagnostic tests for infectious diseases and other health conditions.

Business. Nyrada Inc (NYR.AX) is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Nyrada is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning NYR.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to NYR.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Nyrada Inc (NYR.AX) is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Nyrada is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Nyrada's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and no going-concern language is present in the source documents. This absence of data prevents a full assessment of the company's liquidity position. The valuation snapshot does not provide additional insight into the company's financial health or market valuation.

    In terms of profitability and returns, Nyrada's financial data is insufficient to make a meaningful comparison with industry_config preferred metrics or cohort medians. The lack of detailed financials, including revenue, operating income, and return on invested capital, limits the ability to assess the company's performance relative to its peers.

    Nyrada's revenue concentration and geographic exposure are not disclosed in the available data. The company's segments and geographic breakdown are not provided, making it difficult to evaluate the diversification of its revenue streams or the risks associated with geographic concentration.

    The growth trajectory of Nyrada is unclear due to the absence of outlook data and revenue history. Without numeric deltas or forward-looking guidance, it is not possible to determine the company's expected growth rate or its performance in previous fiscal years.

    Risk factors for Nyrada include the inability to assess liquidity risk, as no balance-sheet inputs are available. The company is also at risk of dilution, although the potential is currently rated as low. No adjustments have been applied to the valuation due to the lack of data, and no specific risk factors are disclosed in the available source documents.

    Recent events and filings for Nyrada are not detailed in the available data. The company's 10-K Risk Factors and other disclosures are not accessible, limiting the ability to evaluate recent developments or strategic changes.

    Key takeaways
    • Nyrada's liquidity position cannot be assessed due to missing balance-sheet data.
    • The company's profitability and returns are indeterminate without comparative financial metrics.
    • Revenue concentration and geographic exposure are not disclosed, limiting risk assessment.
    • Growth trajectory is unclear due to the absence of outlook data and historical revenue figures.
    • Dilution risk is low, but liquidity risk remains unassessed.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    A$0,44
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Nyrada Inc Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    NYR.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage